Monoclonal antibody directed against CD20 antigen
The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of FcγRIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.
1. A monoclonal antibody directed against the CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of said antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of said antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19.
2. The antibody according to claim 1 , wherein the deduced peptide sequence from sequence SEQ ID No. 27 is sequence SEQ ID No. 28, and the deduced peptide sequence from sequence SEQ ID No. 19 is sequence SEQ ID No. 20.
3. The antibody according to claim 1 , produced by a rat hybridoma cell line.
4. The antibody according to claim 3 , produced in the cell line YB2/3HL.P2.G11.16Ag.20, registered at the American Type Culture Collection under ATCC number CRL-1662.
5. The antibody according to claim 1 that is the EMBA603 antibody produced by clone R603, registered under registration number CNCM I-3529 at the Collection Nationale de Cultures de Microorganismes (CNCM).
6. A method, for in vitro activation of FcγRIIIA receptors in immune effector cells comprising combining the antibody according to claim 1 with immune effector cells.
7. A drug composition comprising the antibody according to claim 1 .
8. A method for the treatment of CD20-expressing leukaemia or lymphoma which comprises administering to a patient an effective amount of an antibody according to claim 1 .
9. The method according to claim 8 , in which the leukaemia or lymphoma is a pathology selected from the group consisting of acute B lymphoblastic leukaemia, B-cell lymphoma, mature B-cell lymphoma, small B-cell lymphoma, B-cell prolymphocytic leukaemia, lymphoplasmocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone MALT-type lymphoma, lymph node marginal zone lymphoma with or without monocytoid B cells, splendic marginal zone lymphoma (with or without villous lymphocytes), tricholeucocytic leukaemia, diffuse large B-cell lymphoma, and Burkitt's lymphoma.
10. The method according to claim 9 wherein said pathology is B-type lymphoid leukaemia.
11. A method for the treatment of B-type Chronic Lymphoid Leukaemia (B-CLL), which comprises administering to a patient an effective amount of an antibody according to claim 1 .
12. The method according to claim 8 , wherein said administration further comprises cells which express FcγRs, such as NK (Natural Killer) cells, NKT (Natural Killer T) cells, Tyδ lymphocytes, macrophages, monocytes or dendritic cells.